SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC Cancer Drug, Vandetanib Tied to Substantial Toxicity

November 30, 2010 | 
1 min read
Bloomberg -- AstraZeneca Plc’s experimental thyroid cancer treatment may cause “substantial toxicity,” according to U.S. regulators weighing whether the product should be approved for sale.
Clinical research Phase III
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
 · 
2 min read
 · 
Heather McKenzie
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
 · 
3 min read
 · 
Annalee Armstrong